New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Core Insights - The studies ARCADIA 1 and 2 for atopic dermatitis and OLYMPIA 1 and 2 for prurigo nodularis show significant PP-NRS response at Day 2, highlighting nemolizumab's efficacy and its potential for rapid itch relief [1][1][1] Company Overview - Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. and is now exclusively developed and marketed by Galderma worldwide, except in Japan [1] - In Japan, nemolizumab is marketed as Mitchga® and is approved for treating prurigo nodularis and pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients [1][1] Regulatory Approvals - The U.S. FDA has approved Nemluvio for adults with prurigo nodularis and patients aged 12 years and older with moderate-to-severe atopic dermatitis, in conjunction with topical corticosteroids and/or calcineurin inhibitors when topical therapies are insufficient [1] - Nemluvio has received approval for moderate-to-severe atopic dermatitis and prurigo nodularis from multiple regulatory authorities globally, including the European Union, Australia, Singapore, Switzerland, and the United Kingdom [1][1]